+ subpopulation outside of the endothelium, within subcutaneous VM (SCVM) and intramuscular VM (IMVM). We have also shown the expression of components of the renin-angiotensin system (RAS): (pro)renin receptor (PRR); angiotensin converting enzyme (ACE), angiotensin II receptor 1 (ATIIR1) and angiotensin II receptor 2 (ATIIR2), in both SCVM and IMVM. This study investigated whether the ESC-like subpopulations within SCVM and IMVM expressed the RAS. Methods: Formalin-fixed paraffin-embedded sections of two representative samples from each of the seven SCVM and seven IMVM patients included in our previous studies underwent dual immunofluorescence IF IHC-stained slides were viewed and imaged using an Olympus FV1200 biological confocal laser-scanning microscope, and the images were deconvoluted using cellSens Dimension 1.11 software 2D deconvolution algorithm (Tokyo, Japan). We hypothesize that the ESC-like subpopulations may give rise to cells in VM, and that the RAS may sustain these ESC-like subpopulations. The novel finding of the expression of components of the RAS by the ESC-like subpopulations within SCVM and IMVM suggests that these primitive cells may be a novel therapeutic target by manipulation of the RAS using medications such as β-blockers and ACE inhibitors. In vitro and in vivo functional studies are needed to determine the effects of administration of RAS modulators.
Serendipitous observation of reduced rectal bleeding and anemia in a case of rectosigmoid junction VM following propranolol and celecoxib treatment 3 could be explained by the inhibitory effects of a β-blocker and COX2 inhibitor on the RAS. (Pro)renin receptor, expressed on the endothelium of VM, signaling through the Wnt-β-catenin pathway 4 to maintain pluripotency of ESCs 5 may be the mechanism by which the RAS regulates the ESClike subpopulations within VM. 
